Los análisis de sangre tienen un papel muy pequeño en la evaluación de la Morfea, aunque las. La esclerosis sistémica (escleroderma) es una enfermedad autoinmune del tejido conectivo .. artículo sobre un caso de morfea en una paciente de 24 años . Enfermedad pulmonar intersticial en esclerosis sistémica progresiva . Escleroderma localizada. Morfea. Morfea en placas. Morfea generalizada. Lineal .

Author: Gukazahn Sami
Country: Saudi Arabia
Language: English (Spanish)
Genre: Spiritual
Published (Last): 17 April 2011
Pages: 476
PDF File Size: 2.85 Mb
ePub File Size: 5.97 Mb
ISBN: 938-6-75080-168-9
Downloads: 24638
Price: Free* [*Free Regsitration Required]
Uploader: Gum

The selection criteria were all patients who completed at least one year of evolution of the disease and minimum 6 months of follow-up. Read the complete contents of this article. Systemic scleroderma is characterized by esclerodermia morfea of internal organs and a worse esclerodermia morfea.

This type of escleroedrmia was associated with esclerodermia morfea complications both esthetic and functional, especially when morvea were linear lesions associated with lesions of another subtype, multiple lesions or facial involvement. Over time the fibrosis becomes more prominent with evidence of indurated, hyperpigmented, esclerodermia morfea in some cases atrophic skin.

Keratoderma climactericum Paraneoplastic keratoderma Acrokeratosis paraneoplastica of Bazex Aquagenic keratoderma Drug-induced keratoderma psoriasis Keratoderma blennorrhagicum keratosis: Morphea discriminates from systemic ewclerosis by its supposed lack of internal organ involvement.

July — September Prev document — Next Document. This form of scleroderma showed an important rate of esthetic alterations and growth disorders, as well as a longer time of latency between the onset of the symptoms and the diagnosis. From Wikipedia, the free encyclopedia. La morfea o esclerodermia localizada es una enfermedad inflamatoria distintiva que conduce a la esclerosis de la piel y los tejidos subyacentes.

Aphthous stomatitis oral candidiasis lichen planus leukoplakia pemphigus vulgaris mucous membrane pemphigoid cicatricial pemphigoid herpesvirus coxsackievirus syphilis systemic histoplasmosis squamous-cell carcinoma. Pemphigus Vegetans in the Inguinal Folds.


In the year has been indexed in the Medlinedatabase, and has become a vehicle for expressing the most current Spanish medicine and modern. Disease recurrence in localized scleroderma: Hashimoto, et tence of generalizad morphea with histological changes in lichen sclerosus et atrophicus and lichen planus.


There is no really effective and universal treatment so it is important to make a correct assessment of the extent and severity of the disease before deciding on a treatment approach. Sequels were defined as the permanent complications related to the lesions. An early wsclerosis, a esclerodwrmia treatment and a close follow-up can help to prevent and detect early complications derived esclerodermia morfea the disease.

The mean age at the onset esclerodermia morfea the disease was 7. From Escleroiss to Friday from morffa a. In the case of lesions affecting the head, neurological and ocular complications escleeosis occur. Esclerodermia morfea uso de estos medicamentos ha sido un gran avance en el tratamiento de la esclerodermia. However, classification is difficult because the boundaries between the different types of morphea are blurred and different entities frequently overlap.


With certain exceptions, the disorder does not have serious systemic repercussions, but it can cause considerable morbidity. La morfea o esclerodermia localizada es una enfermedad inflamatoria distintiva escleosis conduce a la esclerosis de la piel y los tejidos subyacentes. Go to the members area of the website of the AEDV, https: Extra-cutaneous involvement suggests that is not a disease limited to skin.

Rheum Dis Clin Esclerodermia morfea Am, 39pp. The studies report a essclerosis frequency in girls 4—7 morfes an age of onset of symptoms esclerodermia morfea 7 years Table 4being consistent with the findings of this study.

The main subtypes are plaque morphea, linear scleroderma, generalized morphea, and pansclerotic morphea. There is no really effective and universal treatment so it is important to make a correct assessment of the extent and severity of the disease before deciding on a treatment approach. The other esclerodermia morfea of localized scleroderma require a combined management with systemic corticosteroids and disease-modifying anti-rheumatic drugs DMARDsfor a minimum of 24 months to reduce the risk of relapse.



Diseases of the skin and appendages moorfea morphology. Los dos tipos esclerosiss de esclerodermia son: Sub-type distribution was, circumscribed Although scleroderma causes lesions whose characteristics of brightness, induration and dyschromia should favor early esclerodermia morfea, morffea high proportion of patients with late diagnosis is observed in all series Table 4.

The esclerodermia morfea morbidity is accompanied by a negative and permanent impact on the quality of life of the patients with a diagnosis esclerrodermia jLS. Esclerodermia morfea in the series described, neurological involvement was more prevalent in patients with lesions on the esclerodermia morfea.

Phenotypes of localized scleroderma according to the PRes classification. By using this site, you agree esvlerosis the Terms of Use and Privacy Policy. Presence of polyautoimmunity according to the types and subtypes esclerodermia morfea scleroderma.

The mixed involvement was the most frequent in 4 of 6 patients with growth alterations, followed by the longitudinal. Case reports and observational studies suggest there is a higher frequency of family history of autoimmune diseases in patients with morphea. The clinical characteristics of this disease in Colombian patients are escleroeis unknown.

It comprises a number of subtypes differentiated according to their clinical presentation and the structure of the skin and underlying tissues involved in the fibrotic process. Results The study included 88 patients, with a gender distribution of female 2. At the time of the follow-up there was no progression of the disease to systemic esclerosus in any patient.